Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1994 May;38(5):1071–1078. doi: 10.1128/aac.38.5.1071

In vitro and in vivo evaluations of A-80556, a new fluoroquinolone.

J J Clement 1, S K Tanaka 1, J Alder 1, C Vojtko 1, J Beyer 1, D Hensey 1, N Ramer 1, D McDaniel 1, D T Chu 1
PMCID: PMC188152  PMID: 8067740

Abstract

A-80556 is a novel fluoroquinolone with potent antibacterial activity against gram-positive, gram-negative, and anaerobic organisms. A-80556 was more active than ciprofloxacin, ofloxacin, lomefloxacin, and sparfloxacin against gram-positive bacteria. A-80556 was particularly active against Staphylococcus aureus (MIC for 90% of isolates [MIC90], 0.12 microgram/ml, relative to fluoroquinolone-susceptible strains) and Streptococcus pneumoniae (MIC90, 0.12 microgram/ml). A-80556 was also the most active of the quinolones tested against ciprofloxacin-resistant S. aureus, with an MIC90 of 4.0 micrograms/ml; that of ciprofloxacin was > 128 micrograms/ml. However, the significance of this activity is not known. A-80556 was slightly less active against Escherichia coli (MIC90, 0.06 microgram/ml) and other enteric organisms than ciprofloxacin (MIC90 for E. coli, < or = 0.03 microgram/ml). A-80556 was slightly less active against Pseudomonas aeruginosa (MIC90, 4.0 micrograms/ml) than ciprofloxacin (MIC90, 2.0 micrograms/ml) and more active against Acinetobacter spp. (respective MIC90s, 0.12 and 0.5 microgram/ml). A-80556 was also the most active compound against anaerobes. Against Bacteroides fragilis, the MIC90 of A-80556 was 2.0 micrograms/ml; that of ciprofloxacin was 16 micrograms/ml. The in vivo efficacy of A-80556 in experimental models with both gram-positive and gram-negative infections was consistent with the in vitro activity and pharmacokinetics and oral absorption in mice.

Full text

PDF
1071

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alder J., Clement J. J. Comparative chemotherapeutic activity of temafloxacin, cefoxitin, clindamycin, imipenem and ampicillin/sulbactam against Bacteroides fragilis in a mouse subcutaneous abscess model. J Antimicrob Chemother. 1993 Feb;31(2):303–311. doi: 10.1093/jac/31.2.303. [DOI] [PubMed] [Google Scholar]
  2. Azoulay-Dupuis E., Bedos J. P., Vallée E., Pocidalo J. J. Comparative activity of fluorinated quinolones in acute and subacute Streptococcus pneumoniae pneumonia models: efficacy of temafloxacin. J Antimicrob Chemother. 1991 Dec;28 (Suppl 100):45–53. doi: 10.1093/jac/28.suppl_c.45. [DOI] [PubMed] [Google Scholar]
  3. Cooper M. A., Andrews J. M., Ashby J. P., Matthews R. S., Wise R. In-vitro activity of sparfloxacin, a new quinolone antimicrobial agent. J Antimicrob Chemother. 1990 Nov;26(5):667–676. doi: 10.1093/jac/26.5.667. [DOI] [PubMed] [Google Scholar]
  4. Hardy D. J., Swanson R. N., Hensey D. M., Ramer N. R., Bower R. R., Hanson C. W., Chu D. T., Fernandes P. B. Comparative antibacterial activities of temafloxacin hydrochloride (A-62254) and two reference fluoroquinolones. Antimicrob Agents Chemother. 1987 Nov;31(11):1768–1774. doi: 10.1128/aac.31.11.1768. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Jones R. N., Aldridge K. E., Barry A. L., Fuchs P. C., Gerlach E. H., Pfaller M. A., Washington J. A., 2nd Multicenter in vitro evaluation of lomefloxacin (NY-198, SC-47111), including tests against nearly 7,000 bacterial isolates and preliminary recommendations for susceptibility testing. Diagn Microbiol Infect Dis. 1988 Aug;10(4):221–240. doi: 10.1016/0732-8893(88)90094-6. [DOI] [PubMed] [Google Scholar]
  6. Jones R. N. Fluoroquinolone resistance. An evolving national problem or just a problem for some physicians? Diagn Microbiol Infect Dis. 1992 Feb;15(2):177–179. doi: 10.1016/0732-8893(92)90046-v. [DOI] [PubMed] [Google Scholar]
  7. King A., Bethune L., Phillips I. The in-vitro activity of temafloxacin compared with other antimicrobial agents. J Antimicrob Chemother. 1991 Jun;27(6):769–779. doi: 10.1093/jac/27.6.769. [DOI] [PubMed] [Google Scholar]
  8. Mazzulli T., Simor A. E., Jaeger R., Fuller S., Low D. E. Comparative in vitro activities of several new fluoroquinolones and beta-lactam antimicrobial agents against community isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1990 Mar;34(3):467–469. doi: 10.1128/aac.34.3.467. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Raviglione M. C., Boyle J. F., Mariuz P., Pablos-Mendez A., Cortes H., Merlo A. Ciprofloxacin-resistant methicillin-resistant Staphylococcus aureus in an acute-care hospital. Antimicrob Agents Chemother. 1990 Nov;34(11):2050–2054. doi: 10.1128/aac.34.11.2050. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Swanson R. N., Hardy D. J., Chu D. T., Shipkowitz N. L., Clement J. J. Activity of temafloxacin against respiratory pathogens. Antimicrob Agents Chemother. 1991 Mar;35(3):423–429. doi: 10.1128/aac.35.3.423. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Thys J. P., Jacobs F., Motte S. Quinolones in the treatment of lower respiratory tract infections. Rev Infect Dis. 1989 Jul-Aug;11 (Suppl 5):S1212–S1219. doi: 10.1093/clinids/11.supplement_5.s1212. [DOI] [PubMed] [Google Scholar]
  12. Wise R., Andrews J. M., Ashby J. P., Matthews R. S. In vitro activity of lomefloxacin, a new quinolone antimicrobial agent, in comparison with those of other agents. Antimicrob Agents Chemother. 1988 May;32(5):617–622. doi: 10.1128/aac.32.5.617. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES